Podcast appearances and mentions of christina weng

In this podcast, expert faculty will discuss the management of diabetic retinopathy (DR).

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-treatment-resistant-dme/15860/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-dme/15859/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-namd/15858/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/a-look-at-the-numbers-cost-of-durable-treatments-in-retinal-disease/15857/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/a-closer-look-at-real-world-strategies-for-treatment-resistant-dme/15856/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/real-world-outcomes-with-durable-treatments-for-retinal-diseases/15855/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-durable-treatment-of-dme/15854/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-durable-treatment-of-namd/15853/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/real-world-treatment-of-retinal-disease/15852/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

In this podcast, expert clinicians will discuss long-acting injectables in RVO management.

CME credits: 0.25 Valid until: 28-09-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-future-is-now-what-weve-learned-about-implantable-anti-vegf-technology/13988/ What are the critical steps to implantation and refill of the PDS? Join Dr. Margaret Chang and Dr. Christina Weng to discover the nuances that retina surgeons need to know about to optimize success and minimize patient risk.

How have innovations in surgical instrumentation created an environment in which surgeons are more comfortable performing vitrectomy for vitreous opacities? In the final episode of the miniseries “Modern Management of Vitreous Opacities,” a panel comprised of Walt Whitley, OD, MBA; Alison Early, MD; John Kitchens, MD; and Christina Weng, MD, MBA, discuss the specific innovations that have improved surgical precision and safety, and review which patients are best suited for prompt referral upon presentation of vitreous opacities.  This editorially independent podcast is supported with advertising.

Which elements of examination must optometrists perfect in order to provide an effective referral for patients with vitreous opacities? On this second episode of the miniseries “Modern Management of Vitreous Opacities,” the panel comprised of Walt Whitley, OD, MBA; Alison Early, MD; John Kitchens, MD; and Christina Weng, MD, MBA, review which elements of examination are most relevant for this condition, which imaging platforms are useful (and not so useful) for documenting vitreous opacities, and the appropriate length of time between patient presentation and surgical intervention.  This editorially independent podcast is supported with advertising.

How can optometrists properly document history for patients presenting with symptomatic vitreous opacities? On this debut episode of the miniseries “Modern Management of Vitreous Opacities,” a panel comprised of Walt Whitley, OD, MBA; Alison Early, MD; John Kitchens, MD; and Christina Weng, MD, MBA, review the specifics of recording symptoms and establishing a timeline for patients with symptomatic vitreous opacities, and discuss whether a standardized methodology for gathering history would have any utility in modern practice.  This editorially independent podcast is supported with advertising.

Host: Jennifer Caudle, DO Guest: Christina Y. Weng, MD, MBA What treatment options are currently available for retinal diseases—and do we need to reevaluate our standard of care? Dr. Jennifer Caudle is joined by Dr. Christina Weng to take a look at current approaches to management for diabetic retinopathy, diabetic macular edema, wet age-related macular degeneration, and macular edema following retinal vein occlusion.

Drs. Audina Berrocal and Christina Weng discuss the publication process, how they decided on topics to include, and their favorite topics regarding overcoming adversity, managing personal relationships as a physician, and more. Women in Ophthalmology is available via Springer and on Amazon (https://www.amazon.com/Women-Ophthalmology-Comprehensive-Guide-Career/dp/3030593347).

As more data are published regarding medical intervention for macular hole closure, retina specialists want to know which patients are best suited for this approach and in which cases it may be most effective. Christina Weng, MD, MBA, invites Brian Do, MD; Mrinali Gupta, MD; and Dimitra Skondra, MD, PhD, to summarize and respond to a pair of retrospective case series that explored the safety and efficacy of drop regimens for macular hole closure. The group discusses the papers' findings and comments on their own experience with medical management of macular holes.  

Peter Kaiser, MD and Christina Weng, MD discuss treatment options in the Covid era, AMD, and the durability of these treatments.

Cytomegalovirus (CMV) retinitis continues to challenge retina specialists. Could use of CMV-specific cytotoxic T lymphocytes be an effective strategy in some patients? And if so, in whom? To answer these questions, Christina Weng, MD, MBA, is joined by study author Mrinali Gupta, MD, and panelists Brian Do, MD, and Dimitra Skondra, MD, PhD. During their discussion, we hear about the structure and findings of the study and learn about how these new data may affect treatment algorithms for patients with newly diagnosed CMV retinitis. 

Perspectives regarding surgery for vitreous opacities (VOs) have shifted in the past several years. How have innovations in surgical instrumentation, visualization, and IOL technology changed how surgeons approach VOs? John Kitchens, MD, sits down with S.K. Steven Houston III, MD, and Christina Weng, MD, MBA, to hear their perspectives on the modern state of VOs, learn about their surgical tactics, and establish how they determine when to send patients to surgery.

As the threat of COVID-19 subsides, scientists are working to make sense of the information that was gathered during the pandemic. Caroline Baumal, MD, asks M. Ali Khan, MD; Vlad Matei, MD; and Christina Weng, MD, MBA, to tackle two papers that analyze data collected during this time. First, they address the strengths and limits of a paper from the infectious disease realm that used history of AMD as a marker for complement inhibition in patients with COVID-19. Then, they parse the details of an article reviewing how real-world high-frequency patients with wet AMD fared when treatment intervals were increased during the height of the pandemic.

In this premiere episode of Equity in Ophthalmology, we sit down with the Co-Editors of the newly released book, Women in Ophthalmology. Dr. Christina Weng and Dr. Audina Berrocal give us an insight into how their bond, background, and current roles today spurred the concept of this passion project to come to fruition. We hear the story of their journey in the field as women in ophthalmology, what we all can bring to the conversation, and the core message of this work from various leaders who contributed. From now until September 22, you can receive a discount by contacting christina.weng@bcm.edu The book is available for order here: https://www.springer.com/us/book/9783030593346

How effective is the use of autologous retina transplant for the treatment of macular holes? Caroline Baumal, MD, moderates a panel comprised of M. Ali Khan, MD; Vladimir Matei, MD; and Christina Weng, MD, MBA, during which they summarize and comment on a recent research paper on this subject published in the journal Ophthalmology. After the break, the group discusses which cases are best suited for this technique and discuss tactics for teaching fellows how to perform autologous retinal transplant.

Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and Christina Weng assess the effect of treating RVO early in its course for the improvement of visual outcomes.

Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and Christina Weng discuss the current use of imaging and biomarkers in the diagnosis as well as prognosis of RVO.

CME credits: 0.25 Valid until: 21-05-2022 Claim your CME credit at https://reachmd.com/programs/cme/frontiers-diabetic-macular-edema-durable-suppression-addressing-health-disparities/12568/ Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.

CME credits: 0.25 Valid until: 21-05-2022 Claim your CME credit at https://reachmd.com/programs/cme/frontiers-diabetic-macular-edema-durable-suppression-addressing-health-disparities/12568/ Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving upon the durability of VEGF suppression. These new treatments that go beyond the current standard of care may help reduce treatment burdens and ultimately improve vision outcomes in DME. Join our two experts, Dr. Christina Weng and Dr. Arshad Khanani, as they discuss these emerging agents, their mechanisms of action, and the latest available data.

CME credits: 0.25 Valid until: 31-03-2022 Claim your CME credit at https://reachmd.com/programs/cme/time-vision-early-recognition-and-management-neovascular-amd-and-rvo/12279/ For patients with retinal vascular disease, time is vision. But there are key components that can help you diagnose early neovascular age-related macular degeneration and retinal vein occlusion before permanent vision loss occurs. Drs. Michael Ip and Christina Weng discuss warning signs, risk factors for progression, and the steps you can take to ensure early diagnosis and improved outcomes for your patients.

Happy holidays, everyone! We're super happy to bring back one of our own co-founders and Sheridan grad, Christina Weng. She is a iXD graduate who works as a product designer at Facebook. Interestingly, Christina was not always in design throughout her post-secondary education as she once attended business school. Christina talks about the process of switching to design, interning early, doing co-op, and yes-competing in hackathons, to get to where she is currently at. She also dives into the interesting science of user research, and team-dynamic. What are some of Christina's early struggles and key realizations? She has y'all covered! 0:08 - Intro 0:48 - Christina introduces herself 1:35 - You did your first internship after 2nd year. Why so early? 5:12 - How was business school? 8:52 - Tell us about your Microsoft garage internship? 12:43 - What did you do the most on your team? 13:53 - Why is research so important nowadays? 17:10 - What are some common mistakes people make when they go through a research process? 22:03 - How does research differ when you have limited hours to work on a project? 24:10 - A lot of designers do not like research, is there a reason for this? 26:18 - What was your first hackathon and why did you decide to get into them? 28:34 - What's the best hackathon you've been to and why? 37:05 - What do you think is the most important activity to do at a hackathon? 38:49 - You and Alex Thompson were the one who had the idea for Hackville; how did creating this go? 42:38 - What was the biggest challenge for you at the moment? 44:45 - Who helped you the most while planning this? 46:11 - How do the challenges in school compare to professional ones? 48:12 - What are the challenges in an all-virtual environment and what should we prepare for as students? 50:55 - Where to find Christina Christina on LinkedIn In addition to personal growth within design, Christina emphasizes the value of growing your network and points to hackathons as the catalyst to beginning her network/career. In fact, not only does Christina note that hackathons grow your network, they also help improve your hard/soft skills as well. For instance, research is very important and even if you as a designer dread it, you can passively learn more about the process by trying out something such as a hackathon. Due to her vast experience sheet with hackathons and other events, she brings forward a lot of many interesting tips and tricks that aren't very well known

In the past decade, a revolution in retinal imaging has advanced the diagnosis, management and treatment of retinal conditions. Dr. Murray interviews retina specialist Dr. Christina Weng of the Baylor College of Medicine Cullen Eye Institute  to discuss how new imaging technologies have advanced retinal care.Resources:Visit the ASRS glossary for descriptions of a wide variety of imaging tools. 

In this episode of The Work Item we interview Christina Weng, product designer at Facebook, about building a career in user experience design from scratch.

With Halloween about two weeks away, people are getting prepared putting together the most detailed costumes, much different than when I was a kid, I might add. While they are transforming themselves into goblins and ghouls using all manner of costume, one item needs to be looked at with some caution--that's novelty contact lenses. There are some definite health risks associated with the use of novelty contacts and the damage they can do to the eye. Assistant professor of ophthalmology at the Baylor College of Medicine, Christina Weng, MD, MBA joins me to discuss novelty contacts and the risks involved.